Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439591 | 1.00 | KMT2A (0.47) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL2160733 | 0.83 | MEN1 (0.54) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL6169765 | 0.82 | KMT2A (0.49) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL29428717 | 0.81 | KMT2A (0.65) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL1325225 | 0.81 | KMT2A (0.65) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL20851004 | 0.81 | KMT2A (0.41) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL13716846 | 0.81 | KMT2A (0.47) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL21617345 | 0.81 | KMT2A (0.47) | KMT2AMEN1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL4225491 | 0.81 | KMT2A (0.69) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL10517153 | 0.80 | KMT2A (0.54) | KMT2AMEN1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-12 | — | — | US | disclosed |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4584265-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-120051470-A | Azaquinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4522608-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-01-30 | — | — | US | disclosed |
| CN-118515653-B | EZH2 specific inhibitor and preparation method and application thereof | 西湖制药(杭州)有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20090030020-A1 | 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030020-A1 | 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030020-A1 | 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1981886-A1 | 7H-PYRIDOÝ3,4-D¨PYRIMIDIN-8-ONES, THEIR MANUFACTURE AND USE AS PROTEIN KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007088014-A1 | 7H-PYRIDO[3,4-D]PYRIMIDIN-8-ONES, THEIR MANUFACTURE AND USE AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088014-A1 | 7H-PYRIDO[3,4-D]PYRIMIDIN-8-ONES, THEIR MANUFACTURE AND USE AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | KMT2A 2867/4885MEN1 3699/4885L3MBTL1 3963/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | KMT2A 709/4885MEN1 86/4885L3MBTL1 192/4885 |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | KMT2A 1376/4885MEN1 1520/4885L3MBTL1 573/4885 |
| US-20090030020-A1 | 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors | MAP3K8, MAP4K2, MAP3K5 | KMT2A 1594/4885MEN1 2099/4885L3MBTL1 3778/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | KMT2A 2492/4885MEN1 3685/4885L3MBTL1 1946/4885 |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | CCNC, CKS1B, CKS2 | KMT2A 3441/4885MEN1 2374/4885L3MBTL1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.